Blue Owl Capital Holdings LP Buys Shares of 874,542 Artiva Biotherapeutics, Inc. $ARTV

Key Points

• Blue Owl Capital Holdings initiated a position of 874,542 Artiva Biotherapeutics shares valued at approximately $8.5 million, representing about 3.54% of the company and 1.3% of Blue Owl’s portfolio.
• Analyst sentiment is broadly positive but mixed, with a “Moderate Buy” consensus and an average price target of $39.00; ratings include one Strong Buy, four Buys and one Sell.
• Artiva shares opened at $11.14 after declining 4.8%, while the company reported a quarterly loss of $0.63 per share in line with estimates. Insiders have purchased nearly 2 million shares worth $16.2 million over the past 90 days.

Blue Owl Capital Holdings LP purchased a new position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 874,542 shares of the company's stock, valued at approximately $8,483,000. Artiva Biotherapeutics comprises about 1.3% of Blue Owl Capital Holdings LP's holdings, making the stock its 16th largest holding. Blue Owl Capital Holdings LP owned about 3.54% of Artiva Biotherapeutics at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in ARTV. Renaissance Technologies LLC increased its stake in Artiva Biotherapeutics by 46.8% in the fourth quarter. Renaissance Technologies LLC now owns 116,200 shares of the company's stock valued at $498,000 after acquiring an additional 37,053 shares during the last quarter. Citadel Advisors LLC raised its position in Artiva Biotherapeutics by 419.3% during the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company's stock valued at $2,291,000 after purchasing an additional 644,658 shares in the last quarter. Marshall Wace LLP bought a new stake in Artiva Biotherapeutics during the fourth quarter worth about $341,000. BNP Paribas Financial Markets lifted its stake in Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company's stock worth $340,000 after purchasing an additional 117,733 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth about $67,000.

Analysts Set New Price Targets

ARTV has been the topic of several recent research reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Weiss Ratings restated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. Needham & Company LLC reaffirmed a "buy" rating and issued a $41.00 target price on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Wall Street Zen upgraded shares of Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Finally, HC Wainwright lifted their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a "buy" rating in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Artiva Biotherapeutics has an average rating of "Moderate Buy" and an average target price of $39.00.

Artiva Biotherapeutics Trading Down 4.8%

Shares of NASDAQ:ARTV opened at $11.14 on Friday. The stock has a market capitalization of $544.63 million, a P/E ratio of -3.38 and a beta of 2.16. The stock's 50-day moving average price is $10.12 and its 200-day moving average price is $8.21. Artiva Biotherapeutics, Inc. has a 12-month low of $2.22 and a 12-month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, meeting the consensus estimate of ($0.63). As a group, research analysts predict that Artiva Biotherapeutics, Inc. will post -2.62 EPS for the current year.

Insiders Place Their Bets

In other news, Director Ra Capital Management, L.P. bought 24,944 shares of the business's stock in a transaction dated Friday, July 31st. The shares were purchased at an average price of $9.93 per share, for a total transaction of $247,693.92. Following the completion of the acquisition, the director owned 17,329,570 shares of the company's stock, valued at approximately $172,082,630.10. This trade represents a 0.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders purchased a total of 1,965,251 shares of company stock valued at $16,188,035 in the last ninety days. Insiders own 1.80% of the company's stock.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.

Want to see what other hedge funds are holding ARTV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source